Search
Paclitaxel Treatment Options
A collection of 2028 research studies where Paclitaxel is the interventional treatment. These studies are located in the United States. Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.
1549 - 1560 of 2028
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Phase II Study of ZD6474 in Advanced NSCLC
Terminated
The goal of this clinical research study is to learn how the drug ZD6474 affects the amount of tumor cell death in the body and the amount of blood that can be supplied to the tumor. The safety of ZD6474 alone and when given with chemotherapy will be studied. In addition, the side effects and response to this treatment will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/13/2016
Locations: University of Texas M.D.Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer
Paclitaxel, Ifosfamide, and Carboplatin Followed By Autologous Stem Cell Transplant in Treating Patients With Germ Cell Tumors That Did Not Respond to Cisplatin
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, ifosfamide, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. An autologous peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy. This may allow more chemotherapy to be given so that more tumor cells are killed.
PU... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/12/2016
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Conditions: Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
A Study of MM-121 With Paclitaxel in Platinum Resistant/ Refractory Advanced Ovarian Cancers
Completed
To determine whether the combination of MM-121 plus paclitaxel is more effective than paclitaxel alone
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/11/2016
Locations: Arizona Center for Cancer Care, Glendale, Arizona +9 locations
Conditions: Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, ifosfamide, carboplatin, and etoposide work in different ways to stop the growth of tumor cells, either by killing them or by stopping them from dividing. Giving chemotherapy with a peripheral stem cell transplant may allow more chemotherapy to be given so that more tumor cells are killed.
The design of this trial is a phase I/II trial of sequential accelerated chemotherapy cycles with taxol/ifosfamide and carboplatin/etoposide administ... Read More
Gender:
ALL
Ages:
15 years and above
Trial Updated:
04/11/2016
Locations: Memorial Sloan-Kettering Cancer Center, New York, New York
Paclitaxel and Carboplatin in Women With Malignant Mixed Mullerian Tumors (MMMT) of the Uterus
Completed
The goal of this clinical research study is to find out if the combination of paclitaxel and carboplatin chemotherapy can shrink or slow the growth of mixed mullerian tumors (MMMT) of the uterus.
Gender:
FEMALE
Ages:
All
Trial Updated:
04/05/2016
Locations: Loma Linda Cancer Institute, Loma Linda, California +3 locations
Conditions: Mixed Tumor, Mullerian
Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer
Terminated
The goal of this clinical research study is to learn about the safety and effectiveness of OSI-774 when combined with standard chemotherapy (carboplatin and paclitaxel) before surgery in the treatment of non-small cell lung cancer.
Gender:
ALL
Ages:
All
Trial Updated:
04/05/2016
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Completed
To demonstrate whether addition of MM-121 to paclitaxel is more effective than treatment with paclitaxel alone, when administered as part of the neoadjuvant treatment in Her2 negative locally advanced operable breast cancer patients.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/30/2016
Locations: Universito of Birmingham atAlabama, Birmingham, Alabama +37 locations
Conditions: ER Positive, Her2 Negative Breast Cancer Patients, Triple Negative Breast Cancer Patients
A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung
Completed
The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN therapeutic reovirus in combination with paclitaxel and carboplatin is effective and safe in the treatment of squamous cell carinoma of the lung.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/29/2016
Locations: Cedars-Sinai Medical Center, Los Angeles, California +16 locations
Conditions: Metastatic or Recurrent Squamous Cell Carcinoma of the Lung
Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer
Completed
The purpose of this study is to demonstrate bioequivalence of IG-001 versus nab-paclitaxel in female patients with metastatic or locally recurrent breast cancer. In addition, the study will compare the safety and tolerance of IG-001 and nab-paclitaxel during the bioequivalence 2-period crossover portion of the study. The study will also evaluate the long-term safety of IG-001 over repeated cycles, up to 4 additional cycles of administration.
Gender:
FEMALE
Ages:
30 years and above
Trial Updated:
03/23/2016
Locations: Sorrento investigational site, Fayetteville, Arkansas +19 locations
Conditions: Metastatic Breast Cancer, Locally Recurrent Breast Cancer
Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer
Terminated
The purpose of the clinical trial is to assess the clinical benefit as measured by time to tumor progression of Abraxane plus hormonal therapy when applied to previously untreated patients with unresectable or metastatic adenocarcinoma of the prostate, as well as to assess safety and tolerability of the study drug regimen and to evaluate secondary efficacy endpoints such as overall survival and duration of response.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/15/2016
Locations: Baylor College of Medicine - Methodist Hospital, Houston, Texas
Conditions: Prostatic Neoplasms
Efficacy and Safety Study of Xyotax to Treat Prostate Cancer
Completed
The purpose of this study is to determine whether Xyotax, a conjugate of the taxane drug paclitaxel, is effective in the treatment of prostate cancer that is no longer responsive to hormone therapy.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/15/2016
Locations: Baylor College of Medicine -Methodist Hospital, Houston, Texas
Conditions: Prostatic Neoplasms
Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery
Completed
This phase I trial studies the side effects and the best dose of cilengitide when given together with paclitaxel weekly in treating patients with solid tumors that have spread nearby or to other areas of the body and cannot be removed by surgery. Cilengitide may stop the growth of tumor cells by blocking blood flow to the tumor. Drugs used in chemotherapy, such as paclitaxel, work in different ways to the stop the growth of tumor cells, either by killing the cells or by stopping them from dividi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2016
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona +2 locations
Conditions: Adult Solid Neoplasm, Estrogen Receptor Negative, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
1549 - 1560 of 2028